CRISPR Therapeutics (CRSP) Stock Analysis & AI Equity Report
CRISPR Therapeutics (CRSP) overview
CRISPR Therapeutics (CRSP) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 3.5m and operating profit of USD -665m; the year-end share price was 52.44 USD and market capitalisation was USD 5,029m. CRISPR Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get CRISPR Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About CRISPR Therapeutics
CRISPR Therapeutics develops CRISPR-based gene-editing therapeutics for serious diseases. Its programs span hemoglobin disorders, in vivo gene editing, gene-edited CAR T cell therapies and regenerative medicine. Its approved therapy CASGEVY treats eligible patients with sickle cell disease or transfusion-dependent beta thalassemia and is developed and commercialized with Vertex. The company also advances delivery and gene-editing technologies.
Generate the CRISPR Therapeutics report
CRISPR Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for CRISPR Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on CRISPR Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.